微芯生物(688321.SH):成都微芯擬對微芯新域增資600萬元
格隆匯6月10日丨微芯生物(688321.SH)公佈,公司全資子公司成都微芯藥業有限公司(簡稱“成都微芯”)的全資子公司微芯新域為滿足業務發展需要,擬將註冊資本由100萬元人民幣增加至1000萬元人民幣,其中成都微芯擬使用自有資金600萬元人民幣認繳微芯新域新增註冊資本600萬元人民幣,成都海新康成企業管理合夥企業(有限合夥)和成都海新睿達企業管理合夥企業(有限合夥)擬分別使用自有資金150萬元人民幣認繳微芯新域新增註冊資本各150萬元人民幣。此次增資完成後,成都微芯合計認繳微芯新域的註冊資本為700萬元人民幣,佔增資後微芯新域註冊資本的70%,微芯新域成為成都微芯的控股子公司
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.